FindTrial
Sign In

Lösungsmittel und Verdünnungsmittel zur Herstellung einer Provokationstestlösung

DRUG3 trials

Sponsors

ROXALL Medizin GmbH, ROXALL Medizin GmbH, ROXALL Medizin GmbH, LETI Pharma S.L.U.

Conditions

Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinaeModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Phase 2

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy
CompletedCTIS2023-505567-37-00
ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline
Start: 2023-08-22End: 2024-10-11Target: 30Updated: 2023-08-22
Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy
CompletedCTIS2023-505880-35-00
ROXALL Medizin GmbH, ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline
Start: 2023-11-10End: 2024-11-07Target: 30Updated: 2023-11-15

Phase 3

A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma
Not yet recruitingCTIS2025-521230-29-00
LETI Pharma S.L.U.Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae
Target: 320Updated: 2025-12-05